On April 27, 2026 Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, reported that an abstract entitled "Combined Safety and Efficacy Results from Three Clinical Studies Evaluating Alpha Radiotherapy for Advanced Pancreatic Cancer" has been accepted at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place May 29 – June 2, 2026. The abstract is expected to be published on May 21, 2026, at 5:00 PM ET on the ASCO (Free ASCO Whitepaper) conference website at View Source
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The ASCO (Free ASCO Whitepaper) Annual Meeting is widely regarded as the largest and most prestigious medical oncology conference in the world, attracting tens of thousands of leading oncologists, researchers, and healthcare professionals from across the globe. Abstract acceptance at ASCO (Free ASCO Whitepaper) is determined through a rigorous, peer-review process and represents recognition of the scientific merit and clinical relevance of the submitted research.
The abstract presents a pooled analysis of safety and efficacy data from three prospective clinical studies evaluating endoscopic ultrasound (EUS)-guided intratumoral Alpha DaRT treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). The studies were conducted at the Jewish General Hospital and Centre Hospitalier de l’Université de Montréal (CHUM) in Montreal, Canada, and at the Hadassah Medical Center in Jerusalem, Israel, enrolling a combined total of 58 patients. Acceptance of the abstract at the ASCO (Free ASCO Whitepaper) Annual Meeting, together with abstract presentation at ASCO (Free ASCO Whitepaper) GI and Digestive Disease Week (DDW) this year, underscores the growing scientific interest and momentum behind the Alpha DaRT pancreatic cancer program.
Uzi Sofer, CEO of Alpha Tau, stated, "The acceptance of an abstract at the ASCO (Free ASCO Whitepaper) Annual Meeting is a wonderful milestone for Alpha Tau and a powerful endorsement of our pancreatic cancer strategy by some of the most prestigious leaders in the field. The continued recognition of our clinical program reflects the growing maturity and strength of our evidence base, and validates the strategic vision behind our multi-study approach to pancreatic cancer: to build one of the most comprehensive intratumoral radiotherapeutic clinical programs in pancreatic cancer worldwide."
Corey Miller, MD, MSc, Director of Therapeutic Endoscopy of the Division of Gastroenterology at the Jewish General Hospital, Assistant Professor of Medicine at McGill University, and the first and presenting author of the abstract, commented, "As the first physician to deliver Alpha DaRT into the pancreas using an endoscopic ultrasound-guided approach, it is deeply meaningful to see how far this program has come. What began as a first-in-human feasibility procedure has evolved into a robust clinical data set, made possible by the close collaboration between gastroenterology, medical oncology and radiation oncology teams. It is this combined effort that enabled the accrual of this cohort and the generation of comprehensive results now accepted at the world’s foremost oncology conference. The EUS-guided intratumoral approach has proven to be technically feasible and well-integrated into clinical workflows, and we look forward to sharing these findings with the global medical community when the abstract is published by ASCO (Free ASCO Whitepaper) and in the Journal of Clinical Oncology."
Robert B. Den, MD, Chief Medical Officer of Alpha Tau stated, "This ASCO (Free ASCO Whitepaper) acceptance is a significant validation of our growing pancreatic cancer clinical program at a critical time. The pooled analysis provides a strong foundation of clinical evidence, and we are actively building on this momentum. Our flagship multicenter IMPACT trial in the United States continues to advance, evaluating Alpha DaRT in combination with chemotherapy in patients with newly diagnosed unresectable pancreatic cancer. In addition, we recently treated the first patient in April in the ACAPELLA trial – a multicenter study in France evaluating Alpha DaRT alongside capecitabine in patients with locally advanced pancreatic cancer. Together, these studies represent an expanding and increasingly global clinical pipeline dedicated to addressing one of the most significant unmet needs in oncology."
About Alpha DaRT
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal intratumoral treatment of solid tumors. Alpha DaRT sources are inserted directly into the tumor, where they release short-lived therapeutic particles that disperse locally with the goal of destroying the tumor. Since the therapeutic effect is confined to a short distance, Alpha DaRT aims to mainly affect the tumor and to spare the healthy tissue around it.
(Press release, Alpha Tau Medical, APR 27, 2026, View Source [SID1234664807])